Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | DRD4 | P21917 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449040 | 0.74 | SCN5A (0.42) | SCN5ADRD2DRD4DRD3PIK3CD | |
| SCHEMBL12489513 | 0.74 | SCN5A (0.42) | SCN5ADRD2DRD4DRD3EPHB3 | |
| SCHEMBL3077299 | 0.74 | SCN5A (0.42) | SCN5ADRD2DRD4DRD3PIK3CD | |
| SCHEMBL3076621 | 0.74 | SCN5A (0.42) | SCN5ADRD2DRD4DRD3PIK3CD | |
| SCHEMBL3064096 | 0.74 | SCN5A (0.42) | SCN5ADRD2DRD4DRD3PIK3CD | |
| SCHEMBL30621194 | 0.74 | SCN5A (0.40) | SCN5ADRD2DRD4DRD3PIK3CD | |
| SCHEMBL18338878 | 0.74 | SCN5A (0.40) | SCN5ADRD2DRD4DRD3PIK3CD | |
| SCHEMBL20476234 | 0.72 | DRD4 (0.33) | DRD2DRD4DRD3EPHB3DRD1 | |
| Hydrochloric Acid SCHEMBL30342081 | 0.71 | CYP19A1 (0.36) | SCN5AIDO1NOTUMDRD2DRD4 | |
| SCHEMBL13212874 | 0.71 | SCN5A (0.59) | SCN5ANOTUMEPHB3PIK3CDCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| EP-1539750-B1 | PYRAZOLOPYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | SCN5A 2888/4885IDO1 1133/4885NOTUM 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.